Evaluation of liver disease progression in the German hepatitis C virus (1b)-contaminated anti-D cohort at 35 years after infection.
about
Interferon therapy in hepatitis C leading to chronic type 1 diabetesGenetic heterogeneity of hepatitis C virus cell entry receptors seems to have no influence on selection of virus variants.Achieving sustained virologic response in hepatitis C: a systematic review of the clinical, economic and quality of life benefitsThe Polymerase Chain Reaction: Essential for the Development of Curative Therapy for Hepatitis CCell death and cell death responses in liver disease: mechanisms and clinical relevanceThe clinical outcomes of chronic hepatitis C in South Korea: A prospective, multicenter cohort study.Disease progression in Chinese patients with hepatitis C virus RNA-positive infection via blood transfusion.Improved Survival Among all Interferon-α-Treated Patients in HCV-002, a Veterans Affairs Hepatitis C Cohort of 2211 Patients, Despite Increased Cirrhosis Among NonrespondersConcurrent Obesity, Diabetes, and Steatosis Increase Risk of Advanced Fibrosis Among HCV Patients: A Systematic Review.Follow-up of patients with chronic hepatitis C and a sustained viral response.Should surveillance for liver cancer be modified in hepatitis C patients after treatment-related cirrhosis regression?Prevention and management of treatment failure to new oral hepatitis C drugs.The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm.The oncologic burden of hepatitis C virus infection: A clinical perspective.Liver-related mortality in countries of the developed world: an ecological study approach to explain the variability.Predicting the development of liver cirrhosis by simple modelling in patients with chronic hepatitis C.Functional connectivity alterations in patients with chronic hepatitis C virus infection: A multimodal MRI study.The efficacy and safety of direct acting antiviral treatment and clinical significance of drug-drug interactions in elderly patients with chronic hepatitis C virus infection.The relationship between liver stiffness measurement and outcome in patients with chronic hepatitis C and cirrhosis: a retrospective longitudinal hospital study.[From the national competence network for viral hepatitis (HepNet) emerged the German Liver Foundation (Deutsche Leberstiftung)].Acute hepatitis C virus infection induces anti-host cell receptor antibodies with virus-neutralizing properties.Successful anti-viral treatment improves survival of patients with advanced liver disease due to chronic hepatitis C.Future complications of chronic hepatitis C in a low-risk area: projections from the hepatitis c study in Northern Norway.Prediction of clinical outcome in advanced hepatitis C-associated liver disease: identification of patients at the highest need for antiviral treatment and surveillance.Strategies to manage hepatitis C virus (HCV) disease burden.Liver disease progression in hepatitis C virus carriers with normal alanine aminotransferase levels.Noninvasive Assessment of Fibrosis Regression in Hepatitis C Virus Sustained Virologic Responders.Editorial: the burden of chronic liver disease - an ecological method sees the wood for the trees.Editorial: the burden of chronic liver disease - an ecological method sees the wood for the trees. Authors' reply.Reply
P2860
Q28080876-F1B9E70B-8CC3-4C7A-B170-30D13CC4A9D3Q33556862-15983067-6576-4C6D-97E5-E47A93FAD8E8Q34987336-D67A1732-8254-45F7-85A4-5F60995248A3Q35843443-2806D801-5F2C-4CA1-939B-FF1FC3158221Q35938040-71410730-208A-4193-8C2C-8F6C985495FFQ37226231-300815D0-AF0D-4A0A-9A19-0F90F1C2A930Q37406708-0A116178-D4BE-4199-8450-3693CCA9EDCEQ37641036-BF6E933F-AB4D-428C-844A-49622303C122Q38542209-D81642AB-8263-429C-A252-8EE05E260C53Q38685584-A36BE618-2570-496C-B54D-968149D67319Q38758591-A6D094C6-1AE5-4102-BE45-141272DCF0A8Q38826624-B9E73E0A-2CFA-458F-AECB-8340E2FAE31BQ39213684-6A1DD742-D7E9-47BD-84D0-D027107270EBQ39418450-0FB98DD3-555A-441D-8178-AB2770EDC70DQ39758401-A9E6DC1C-1DA2-4BD1-AC7E-2C98F27A67C0Q40305694-D68CF0DE-8989-4D8B-A8F7-E4F5EE1A8344Q40463925-A6BE306E-C0FE-45BD-AB1C-15C0CF560AAEQ40567336-39081445-594B-4BEB-9094-78F650A6C5F2Q40654311-BF3890AB-AE42-464A-BFF0-8A7E562FDB00Q40767750-7A16DCDD-655A-4563-B03C-370A6EFAC6D8Q41203252-E0CD79CA-461E-40C1-A1C5-0C36CEA35A24Q41535486-34B44C43-E7C8-40B4-B6DA-78FD50CE315CQ41711879-C8B5807E-FDA7-45EB-AC81-F59B8E026D3DQ42211257-D179950A-7AAC-4C66-B8F4-E849861BBA81Q42226125-8013CE41-62D7-467F-9D2A-6F0493A129ADQ45347245-851F0E35-0C55-4892-9BCB-7DE858C21EE3Q47546971-8C9D13B9-873E-4FEA-A51C-8771CE97CCC6Q48130564-8D6D23D9-300F-4101-B900-8B3EAE7AAD33Q51152151-3E5668FE-92C7-443C-85BA-65099778BDDFQ58096473-8737091E-9FC2-4936-A6A7-D04A1FBEE4E9
P2860
Evaluation of liver disease progression in the German hepatitis C virus (1b)-contaminated anti-D cohort at 35 years after infection.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Evaluation of liver disease pr ...... t at 35 years after infection.
@en
Evaluation of liver disease progression in the German hepatitis C virus
@nl
type
label
Evaluation of liver disease pr ...... t at 35 years after infection.
@en
Evaluation of liver disease progression in the German hepatitis C virus
@nl
prefLabel
Evaluation of liver disease pr ...... t at 35 years after infection.
@en
Evaluation of liver disease progression in the German hepatitis C virus
@nl
P2093
P2860
P356
P1433
P1476
Evaluation of liver disease pr ...... t at 35 years after infection.
@en
P2093
Alexander Zipprich
East German HCV Study Group
Franziska Richter
Hannelore Tenckhoff
Ingolf Schiefke
Janett Fischer
Kurt Grüngreiff
Manfred Wiese
Micha Löbermann
Thomas Berg
P2860
P356
10.1002/HEP.26644
P407
P577
2013-11-18T00:00:00Z